Safety of Laparoscopy Assisted Gastrectomy for Gastric Cancer, Including Advanced Cancers.
10.7602/jmis.2015.18.3.79
- Author:
Eun Mee PARK
1
;
Hyung Ook KIM
;
Byung Ho SON
;
Jun Ho SHIN
;
Sung Ryol LEE
Author Information
1. Department of Surgery, Sungkyunkwan University School of Medicine, Seoul, Korea. dackang1@gmail.com
- Publication Type:Original Article
- Keywords:
Gastric cancer;
Laparoscopy-assisted surgery;
Overall survival
- MeSH:
Disease-Free Survival;
Gastrectomy*;
Humans;
Laparoscopy*;
Prognosis;
Recurrence;
Retrospective Studies;
Stomach Neoplasms*
- From:Journal of Minimally Invasive Surgery
2015;18(3):79-85
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Laparoscopy-assisted gastrectomy (LAG) is considered an alternative treatment option for gastric cancer. LAG is safe, however the long-term oncologic efficacy and survival of patients including those with advanced gastric cancer have not been assessed. The aim of this study was to evaluate long-term outcomes and survival of patients with gastric cancer, including advanced cases, who underwent LAG performed by a single surgeon. METHODS: Between January 2006 and December 2010, 161 patients with gastric cancer underwent LAG performed by a single surgeon. Clinicopathological data were collected retrospectively along with data on survival and prognosis. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method. RESULTS: A total of 161 patients diagnosed with gastric cancer underwent LAG. Postoperative morbidity occurred in 12 patients. The median OS was 67.0 months (range, 1.0~97.0 months), and the median DFS was 67.0 months (range, 1.0~97.0 months). T stage, N stage, TNM stage, lymphatic invasion, and venous invasion influenced overall survival and disease recurrence. The OS rates according to N stage were 96.8% for N0, 94.4% for N1, 45.5% for N2, and 42.9% for N3. CONCLUSION: The current study showed that LAG for gastric cancer, including advanced gastric cancer, is technically feasible with acceptable long-term oncologic outcomes.
